Protected Predictive Technology

Allarity has previously secured patent protection for the stenoparib DRP in the United States, with protection extending into April 2042, as well as in certain European jurisdictions and Australia. Related patent applications remain pending in additional international markets. The company's proprietary DRP technology has demonstrated the ability to provide statistically significant predictions of clinical outcome following drug treatment across dozens of retrospective and prospective clinical studies.